Book Profits On Puma Biotechnology – Cramer’s Lightning Round (8/7/17) – Seeking Alpha

Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Monday, August 7.

Philip Morris International (NYSE:PM): "No, don't sell it. I think they have a lot more optionality. I would not sell that here. And remember, I think the dollar's getting very weak still."

Blue Apron (NYSE:APRN): Cramer doesn't see upside.

International Game Technology (NYSE:IGT): It's an inexpensive stock but does not have a growth catalyst.

Eaton Corp (NYSE:ETN): Their quarter was not good. Cramer prefers Honeywell (NYSE:HON) or 3M (NYSE:MMM).

DaVita (NYSE:DVA): No. Cramer prefers Boston Scientific (NYSE:BSX) in that group.

Puma Biotechnology (NYSE:PBYI): It has had a big run. Book profits.

Masimo Corp (NASDAQ:MASI): Cramer just prefers Intuitive Surgical (NASDAQ:ISRG) in that group.

::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::

Jim Cramer's Action Alerts PLUS: Check out Cramer's multi-million dollar charitable trust portfolio and uncover the stocks he thinks could be HUGE winners. Start your FREE 14-day trial now!

Get Cramer's Picks by email - it's free and takes only a few seconds to sign up

Visit link:
Book Profits On Puma Biotechnology - Cramer's Lightning Round (8/7/17) - Seeking Alpha

Valuation Dashboard: Healthcare – Update – Seeking Alpha

This article series provides a monthly dashboard of industries in each sector of the GICS classification. It compares valuation and quality factors relative to their historical averages.

Biotechnology is close to its historical average in valuation ratios but below it in profitability measured in ROE. Pharmaceuticals look good in Price/Earnings and Price/Free Cash Flow but very bad in Price/Sales and ROE. Other healthcare industries look overvalued by at least 20%. Life Science Tools/Services are significantly above their baseline in profitability, which may partly justify overpricing. Healthcare Equipment is the less appealing group, significantly worse than its historical averages in all metrics.

Since last month:

P/E is stable in Managed Healthcare, Healthcare Technology, and Life Science Tools and has deteriorated in Biotechnology, Pharmaceuticals, and Healthcare Equipment.

P/S has improved in Healthcare Technology and Biotechnology and deteriorated in Life Science Tools, Pharmaceuticals, and Healthcare Equipment.

P/FCF has improved in Healthcare Equipment, Managed Healthcare, and Life Science Tools and deteriorated in Biotechnology, Pharmaceuticals, and Healthcare Technology.

ROE has improved in Life Sciences Tools and deteriorated in Healthcare Technology and Pharmaceuticals.

In one trailing month, the SPDR Select Sector Healthcare ETF (XLV) and the S&P 500 Pharmaceuticals ETF (XPH) have outperformed the SPDR S&P 500 ETF (SPY) by about 2%, whereas the Nasdaq Biotechnology ETF (IBB) did so by about 6%.

The five best performers among S&P 500 Healthcare stocks in this period are Biogen Inc. (NASDAQ:BIIB), Gilead Sciences Inc. (NASDAQ:GILD), Incyte Corp. (NASDAQ:INCY), Perrigo Company Plc (NASDAQ:PRGO), and Varian Medical Systems Inc. (NYSE:VAR).

The stocks listed below are in the S&P 1500 index, cheaper than their respective industry factor for Price/Earnings, Price/Sales, and Price/Free Cash Flow. The 10 companies with the highest Return on Equity are kept in the final selection.

I update every month 8 lists like this one covering all sectors (some sectors are grouped). The 8 lists together have returned about 25% in 2016. If you want to stay informed of updates, click "Follow" at the top of this page. My Marketplace Subscribers have an early access to the stock lists before they are published in free articles. Past performance is not a guarantee of future result. This is not investment advice. Do your own research before buying.

Amgen Inc. (NASDAQ:AMGN)

BIOTECH

Biogen Inc. (BIIB)

BIOTECH

Bioverativ Inc. (NASDAQ:BIVV)

BIOTECH

Eagle Pharmaceuticals Inc. (NASDAQ:EGRX)

BIOTECH

Gilead Sciences Inc. (GILD)

BIOTECH

AMN Healthcare Services Inc. (NYSE:AMN)

HCAREPROVID

DaVita Inc. (NYSE:DVA)

HCAREPROVID

McKesson Corp. (NYSE:MCK)

HCAREPROVID

INC Research Holdings Inc. (NASDAQ:INCR)

MEDEQUIP

Phibro Animal Health Corp. (NASDAQ:PAHC)

PHARMA

I take 4 aggregate industry factors provided by portfolio123: Price/Earnings (P/E), Price-to-Sales (P/S), Price-to-Free Cash Flow (P/FCF), and Return on Equity (ROE). My choice has been justified here and here. Their calculation aims at limiting the influence of outliers and large caps. They are reference values for stock picking, not for capital-weighted indices.

For each factor, I calculate the difference with its own historical average: to the average for valuation ratios, from the average for ROE, so that the higher is always the better. The difference is measured in percentage for valuation ratios, not for ROE (already in percentage).

The next table reports the 4 industry factors. There are 3 columns for each factor: the current value, the average (Avg) between January 1999 and October 2015 taken as an arbitrary reference of fair valuation, and the difference explained above (D-xxx).

P/E

Avg

D- P/E

P/S

Avg

D- P/S

P/FCF

Avg

D- P/FCF

ROE

Avg

D-ROE

Health Care Equipment

46.58

27.18

-71.38%

4.28

3.18

-34.59%

43.55

30.51

-42.74%

-36.43

-12.14

-24.29

Managed Health Care

26.67

20.88

-27.73%

1.07

0.85

-25.88%

21.15

17.75

-19.15%

8.03

5.78

2.25

Health Care Technology*

78.89

56.13

-40.55%

3.18

3.39

6.19%

40.42

35.77

-13.00%

-20.98

-6.2

-14.78

Biotechnology

40.12

39.78

-0.85%

35.81

29.01

-23.44%

34.09

43.74

22.06%

-76.88

-64.42

-12.46

Pharmaceuticals

28.6

Visit link:
Valuation Dashboard: Healthcare - Update - Seeking Alpha

Wave Life Sciences Announces Publication of Paper in Nature Biotechnology Establishing the Importance of … – Business Wire (press release)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Wave Life Sciences Ltd. (NASDAQ:WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, today announced the publication of a new paper in the September issue of Nature Biotechnology. The paper describes a breakthrough method to produce antisense oligonucleotide (ASO) therapeutics with high stereochemical purity as well as rational drug design to control pharmacologic properties in nucleic acid therapeutics drug development more broadly. This publicationof Waves stereopure chemistry platform represents a significant scientific advancement for the oligonucleotide field.

The paper, entitled "Control of phosphorothioate stereochemistry substantially increases the efficacy of antisense oligonucleotides," details a proprietary synthesis process developed by Wave. By applying this method, Wave was able to overcome previous barriers to the scalable synthesis of stereochemically pure oligonucleotides.

These findings represent a breakthrough in the nucleic acid field, said Chandra Vargeese, Ph.D., head of Drug Discovery at Wave Life Sciences. This paper outlines early foundational principles discovered by Wave to engage RNase H1 that can be applied to any ASO sequence. We have demonstrated that stereochemistry plays a central role in oligonucleotide drug design, with the potential to improve stability, duration of activity and specificity. With continued advancements in our proprietary synthesis process, we have developed a highly efficient manufacturing system that may allow for these key findings to translate into next generation nucleic acid therapeutics. We continue to leverage these initial findings to further build our knowledge base and expand our platform capabilities beyond antisense, including our ongoing work in exon skipping, single stranded RNAi and other modalities.

Wave's researchers synthesized rationally designed stereopure isomers of mipomersen, an FDA approved drug comprised of 524,288 stereoisomers. These researchers demonstrated that phosphorothioate stereochemistry substantially impacts the pharmacologic properties of ASOs. Furthermore, their work identified a stereochemical code that can be rationally designed in the stereopure ASOs that promotes targeted RNA cleavage by RNase H1, and that provides a more durable response in mice than is achieved by stereorandom ASOs. Waves research also demonstrated that this stereochemical code improved pharmacologic properties both with mipomersen and with a second sequence (conjugated with GalNAc) that targets APOC3. This stereochemical platform provides a foundation for Wave's current pre-clinical and clinical programs, including two recently initiated trials in Huntington's disease (PRECISION-HD1 and PRECISION-HD2).

"These findings provide a powerful demonstration of Wave's stereopure oligonucleotide platform and its potential to rationally design therapies targeting currently untreatable genetic conditions," said Greg Verdine, founder, board member of Wave Life Sciences. "The ability for the first time to exert precise, synthetically programmable control over the chemistry and stereochemistry of ASOs, and the pharmacologic benefits observed for stereochemical optimization as demonstrated in this paper, offer a compelling basis for Wave's novel approach toward advancing safer and more effective nucleic acid therapies."

About Wave Life Sciences

Wave Life Sciences is a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases. Our chemistry platform enables the creation of highly specific, well characterized oligonucleotides designed to deliver superior efficacy and safety across multiple therapeutic modalities. Our pipeline is initially focused on neurological disorders and extends across several other therapeutic areas.

Forward Looking Information

This press release contains forward-looking statements, including statements relating to the significance of the paper; the importance of the papers findings in the field of nucleic acid therapeutics; the distinguishing features of Waves drug development platform and the potential benefits thereof. These statements may be identified by words such as believe, expect, may, plan, potential, will and similar expressions, and are based on current beliefs and expectations. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including risks and uncertainties associated with Waves stereopure chemistry platform, the drug development and regulatory approval process; and the commercialization, development and acceptance of therapies with new technologies, as well as other risks and uncertainties that are described in the Risk Factors section of Waves most recent annual or quarterly report filed with the U.S. Securities and Exchange Commission. Any forward-looking statements speak only as of the date of this press release and the parties assume no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Read the original post:
Wave Life Sciences Announces Publication of Paper in Nature Biotechnology Establishing the Importance of ... - Business Wire (press release)

Solving Africa’s food insecurity through biotechnology – NIGERIAN TRIBUNE (press release) (blog)

There is an increasing focus on science being linked to providing practical solutions to agricultural problems. There is also increasing awareness of technology, although the channels used for information and creating change in the way information is passed and understood by the receiver are poorly developed.

Biotechnology is no longer a new technology in Africa; some countries in Africa have adopted the technology, while some other countries are currently conducting confined field trial for the technology.

In Nigeria, Genetically Modified Organisms (GMOs) which is a component of biotechnology is currently undergoing confined field trial in various locations. It is expected that in the next three years, the commercialisation of the BT cotton will commence in the country.

Africa as a continent in the recent past have suffered a high level of food insecurity following the actions and inaction of various governments to put sustainable policies to fast track agricultural development.

Some countries in Africa have also experienced food shortage due to some natural disaster which includes flood, pest attack, insect infestation and drought.

In some countries, the uses of manual and outdated method of farming have contributed immensely to the countrys dependence for food supply on some developed countries that have used technology to advance their agricultural sector.

Biotechnology have been adopted by various countries to develop their agricultural sector which have made them self sufficient in food production and earned them foreign exchange through exportation of agricultural products.

Many African countries have been skeptical of adopting biotechnology following some baseless and unscientific criticism from some quarters on the new technology.

This singular act of negligence and gullibility exhibited by these African countries have further subjected them to being importers of food products from countries that have developed there agricultural technology.

In Ghana, the commercialization of GMOs may not be possible until the court injunction issued against its further release in Ghana have been concluded.

However, good news emerged as the Plant Breeders Bill was said to be underway and soon to be signed into law in Ghana to protect the developers of the technology and encourage the investment in science and technology beyond the countrys budget.

Instead of the critics of the technology to say science is not good at all, they should discuss on its deployment which can be useful to our economy.

The Open Forum On Agricultural Biotechnology (OFAB), Ghana have visited all the regions in Ghana and information materials on biotechnology have been translated into local languages.

It is worthy to note that the Ghanaian government does not fund science, to this end, funding is needed to scale up educational activities on modern biosafety issues in Ghana.

In Nigeria, it is sad to note that the country has one of the lowest usage rates of agriculture inputs and ranks the lowest on agriculture indices of mechanization and irrigation.

Insect and pest problems, climate change issues and increasing population were also attributed as the reasons for poor productivity.

Meanwhile, there are some Genetically Modified crops that can withstand insects and pests attack, while some are drought resistant. These crops if adopted could be used by farmers to upscale the countrys food production without the crops been damaged by pests and insects.

However, Maize, cotton, rice, cassava, Sorghum (ABS) have been said to be the first GM crops to be introduced in Nigeria for commercialisation soon.

It is also worthy of note that the Biosafety law was signed in Nigeria in 2015 which gave rise to the establishment of regulatory agency, National Biosafety Management Agency (NBMA) same year.

Since its establishment, NBMA has carried out 3 approvals and accredited research institutes and universities for GM research.

OFAB Nigeria in its advocacy drive has carried out advocacy visits, capacity building, Seeing is Believing Tours, workshops and seminars, radio and tv programs, social media campaigns to enlighten the public and policy holders with the right information on the safety of biotechnology and its practices.

In Burkina Faso, Cotton is one of the major driver of the countrys economy, 85 per cent of population of Burkina Faso is active in agriculture and cotton is its number one cash crop contributing 25 per cent of agricultural income.

There is evidence that cotton is locomotive for cereal crops such as maize and sorghum in Burkina Faso.

In Burkina Faso, necessary steps have been taken towards the release of GM cotton- Pre-release trials, BT cotton seed multiplication, Commercial production of GM Bollgard II Cotton and cultivation field, commercial production since 2009.

BT cotton (GM Cotton) have pushed Burkina Faso in the cotton production ranking from 11th in 1990s to 1st position in Africa since 2010.

Genetically Modified Organisms is a technology which African countries cannot afford to neglect, this new technology will help African countries to upscale its food production, guarantee food security and earn foreign exchange for the countries.

The era of dependence on food importation should be over in Africa. The governments in Africa should look for possible ways of adopting biotechnology in food production, this will go along way to addressing food insecurity and guarantee self-sufficiency in food production.

Follow this link:
Solving Africa's food insecurity through biotechnology - NIGERIAN TRIBUNE (press release) (blog)

Biotech: No Downside Risk Here – Barron’s


Barron's
Biotech: No Downside Risk Here
Barron's
Both the iShares Nasdaq Biotechnology ETF (IBB) and the SPDR S&P Biotech ETF (XBI) have risen 1.5% and 2.4% respectively, so far on Thursday. Oppenheimer's Leah Rush Cann notes that biotech stocks are trading at a 30% premium to the market.
Compton Capital Management Inc. RI Boosts Position in iShares NASDAQ Biotechnology Index (IBB)The Cerbat Gem
Neville Rodie & Shaw Inc. Boosts Position in iShares NASDAQ Biotechnology Index (IBB)Sports Perspectives
Alethea Capital Management LLC Maintains Stake in iShares NASDAQ Biotechnology Index (IBB)Chaffey Breeze
BBNS
all 23 news articles »

Read more here:
Biotech: No Downside Risk Here - Barron's

The Bears And Bulls Square Off On Puma Biotechnology, Inc. (PBYI) – NY Stock News


NY Stock News
The Bears And Bulls Square Off On Puma Biotechnology, Inc. (PBYI)
NY Stock News
Puma Biotechnology, Inc. (PBYI) has presented a rich pool of technical data in recent sessions. These are the trends we've been tracking and how we feel they should be played in the current environment. Successful trading professionals know that in ...
Abercrombie & Fitch Company - ANF - Stock Price Today - ZacksZacks

all 67 news articles »

See the original post here:
The Bears And Bulls Square Off On Puma Biotechnology, Inc. (PBYI) - NY Stock News

iShares NASDAQ Biotechnology Index (IBB) Upgraded at Vetr Inc. – The Cerbat Gem


BBNS
iShares NASDAQ Biotechnology Index (IBB) Upgraded at Vetr Inc.
The Cerbat Gem
iShares NASDAQ Biotechnology Index logo Vetr upgraded shares of iShares NASDAQ Biotechnology Index (NASDAQ:IBB) from a hold rating to a buy rating in a research report report published on Wednesday, April 5th. They currently have $298.93 target ...
iShares NASDAQ Biotechnology Index (IBB) Stake Increased by ...Markets Daily
iShares NASDAQ Biotechnology Index (IBB) Rating Increased to Buy at Vetr Inc.Transcript Daily
iShares NASDAQ Biotechnology Index (IBB) Stock Rating Upgraded ...Sports Perspectives
BBNS -Chaffey Breeze -Petro Global News 24
all 16 news articles »

See original here:
iShares NASDAQ Biotechnology Index (IBB) Upgraded at Vetr Inc. - The Cerbat Gem

Harbour Investment Management LLC Invests $4.559 Million in iShares NASDAQ Biotechnology Index (IBB) – The Cerbat Gem


Investopedia
Harbour Investment Management LLC Invests $4.559 Million in iShares NASDAQ Biotechnology Index (IBB)
The Cerbat Gem
iShares NASDAQ Biotechnology Index logo Harbour Investment Management LLC bought a new position in iShares NASDAQ Biotechnology Index (NASDAQ:IBB) during the first quarter, according to its most recent filing with the Securities and Exchange ...
The 737 Shares in iShares NASDAQ Biotechnology Index (IBB) Acquired by Sawtooth Solutions LLCBangaloreWeekly
Lucas Capital Management Has $2.254 Million Stake in iShares NASDAQ Biotechnology Index (IBB)Sports Perspectives
iShares NASDAQ Biotechnology Index (IBB) Earns Daily News Sentiment Rating of 0.39BBNS
Markets Daily -Transcript Daily -Chaffey Breeze
all 30 news articles »

Excerpt from:
Harbour Investment Management LLC Invests $4.559 Million in iShares NASDAQ Biotechnology Index (IBB) - The Cerbat Gem

Pac-Man meets biotechnology – Phys.org – Phys.Org

April 26, 2017 The authors artwork, illustrating the article, was also featured on the cover of Lab on a Chip. Credit: Royal Society of Chemistry

Scientists in the U.S have a designed a computer game that could help with biomedical research.

Scientists increasingly use miniscule robots to solve a range of problems, from cancer treatment to water purification. And, as with a lot of technology, the race is on to make these devices ever smaller.

However there is a limit to how far you can go with a mechanical device moving parts such as motors can physically only get so small.

So scientists are looking to the natural world to help. Single cell organisms, such as bacteria and algae, could make the parts in the miniaturised robots move, without the need for an external power source.

Such organisms respond to changes in their environment such as light and food by moving, and if these movements can be harnessed, we can use them as motors.

In a new paper just published in Lab on a Chip, Ingmar Riedel-Kruse and fellow scientists from Stanford University in the U.S. have demonstrated the use of one such organism, in the form of a game.

It's based on Euglena gracilis, single cell algae that move in response to changes in strong light. In the game, the organisms are directed around a maze or "captured" in a space on the screen by the users turning lights on and off. The ability to control the movement of the algae demonstrates their potential application in mini, single cell organism-driven motors.

In this set-up, the algae's movements are programmable a promising first step towards creating a microcomputer built on biotechnology.

Explore further: Single cell organism firm joins top ranks of Japan bourse

More information: Amy T. Lam et al. Device and programming abstractions for spatiotemporal control of active micro-particle swarms, Lab Chip (2017). DOI: 10.1039/C7LC00131B

The high-tech titans of Japanese industry were joined Wednesday in the major league of the Tokyo Stock Exchange by a company exploiting the 500-million-year-old science of a single cell organism.

Diatoms are unicellular algae that are native in many waters. They are a major component of marine phytoplankton and the food base for a large variety of marine organisms. In addition, they produce about one fifth of the ...

A new 3-D printed, easily assembled smartphone microscope developed at Stanford University turns microbiology into game time. The device allows kids to play games or make more serious observations with miniature light-seeking ...

Scientists at the John Innes Centre have discovered that Euglena gracilis, the single cell algae which inhabits most garden ponds, has a whole host of new, unclassified genes which can make new forms of carbohydrates and ...

Scientists at the Swedish Museum of Natural History have found fossils of 1.6 billion-year-old probable red algae. The spectacular finds, publishing on 14 March in the open access journal PLOS Biology, indicate that advanced ...

In an algae-eat-algae world, it's the single-celled photosynthetic organisms at the top (layer of the ocean) that absorb the most sunlight. Underneath, in the sublayers, are cryptophyte algae that must compete for photons ...

The ancient Chinese practiced copromancy, the diagnosis of health based on the shape, size and texture of feces. So did the Egyptians, the Greeks and nearly every ancient culture. Even today, your doctor may ask when you ...

Dan Harrington makes his living unearthing marine worms by hacking away at mudflats with a tool that resembles the business end of an old steel rake.

Looking for a better beer or single malt Scotch whiskey? A team of researchers at the University of California, Riverside may have you covered. They are among a group of 77 scientists worldwide who have sequenced the complete ...

In the spring when water temperatures start to rise, rainbow trout that have spent several years at sea traveling hundreds of miles from home manage, without maps or GPS, to find their way back to the rivers and streams where ...

(Phys.org)A pair of researchers with Harvard and Yale Universities has conducted a study of optimal human throwing techniques and found which work best under which conditions. In their paper published in the journal Royal ...

Giacomo Cavalli's team at the Institute of Human Genetics (University of Montpellier / CNRS), in collaboration with the French National Institute for Agricultural Research (INRA), has demonstrated the existence of transgenerational ...

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

See the original post here:
Pac-Man meets biotechnology - Phys.org - Phys.Org

Plandai Biotechnology Sets Aggressive Agenda for 2017 – Yahoo Finance

NEW YORK, NY--(Marketwired - April 19, 2017) - Planda Biotechnology (PLPL) recently presented investors with its outlook for 2017 and a number of milestones that the company plans to accomplish in 2017. Planda's plans are certainly aggressive and representative of the new Chief Operating Officer (COO) -- someone we feel is ideally suited to move the company forward. It didn't take long at all for the new COO, Callum Cottrell-Duffield, to put his stamp on the company's future.

Three weeks ago Planda named Callum Cottrell-Duffield as its new COO, a role that will have him running the day-to-day operations of the company. In the time since being named COO, he has put together a plan to not only get Planda back on track, but to also move it aggressively into the future. With Planda shifting from purely a research and development biotechnology company to a company that is more focused on operations and sales, Callum Cottrell-Duffield is the ideal person to run Planda's day-to-day activity.

After all, he has been there from the beginning where he helped to prepare the company's 8,000-acre tea estate to grow, harvest and produce Planda's signature product, the highly bioavailable Phytofare Catechin Complex. Last year when that signature product was available for mass production and ready to market on a much broader scale, it was Callum Cottrell-Duffield who led the company's sales and marketing team. He has traveled throughout Africa, the United States, Europe, Asia and South America to tell the Planda story, and he has become the face of the company to the industry and to the large buyers who are either current clients or interested in developing a relationship with Planda worldwide.

In the company's latest news release, the COO highlighted several areas where he expects to see improvement and areas where Planda can realize growth. Among those items, Callum Cottrell-Duffield said that he (i) has placed getting the company "current" with its SEC filings at the top of his agenda, (ii) expects to increase production and to continue growing sales with Planda's existing customers as well as gaining traction in the market, which should lead to the addition of new customers all in an effort to make Planda cash flow positive and profitable by the end of 2017, (iii) recently signed a financing agreement that will provide the necessary capital to see the company through until it becomes cash flow positive.

With the appointment of Callum Cottrell-Duffield to COO, the company's CEO, Roger Baylis-Duffield, can now focus his efforts as a scientist on spearheading the company's clinical trials and developing new products for Planda to market. In the company's research and development efforts, the CEO will be busy with a number of major studies this year.

According to the COO, Planda's work in the clinic will include:

Additionally, Planda has granted a research license to Protext Mobility to develop pharmaceutical applications involving Phytofare. Protext will be conducting a human study using Phytofare to regulate glucose levels in Type 2 diabetics as well as, taking over the research to establish a platform for producing non-psychoactive Cannabis. Planda states that the plan for Protext is to produce a Phytofare complex containing bioavailable cannabinoids, cannabinoid acids, and polyphenols that will be formulated into an oral delivery system.

Needless to say, with success in these studies, these are all areas where Planda could develop much-needed products that could, in turn, drastically improve the company's bottom line. For a full look into the COO's agenda for 2017, read Planda's latest news release here:

http://finance.yahoo.com/news/plandai-biotechnology-chief-operating-officer-162043100.html

About Stock Market Media Group

Stock Market Media Group is a Content Development IR firm offering a platform for corporate stories to unfold in the media with research reports, corporate videos, CEO interviews and feature news articles.

We may from time to time include our own opinions about our featured companies, their businesses, markets and opportunities. Any opinions we may offer are solely our own, and are made in reliance upon our rights under the First Amendment to the U.S. Constitution, and are provided solely for the general opinionated discussion of our readers and viewers. Our opinions should not be considered to be complete, precise, accurate, or current investment advice, or construed or interpreted as research. Any investment decisions you may make concerning any company are solely your responsibility based on your own due diligence. Our publications are provided only as an informational aid. We encourage you to invest carefully and read the investor information available at the web site of the U.S. Securities and Exchange Commission at: http://www.sec.gov. We also recommend as a general rule, that before investing in any securities you consult with a professional financial planner or advisor, and you should conduct a complete and independent investigation before investing in any security after prudent consideration of all pertinent risks.

Read More

We are not a registered broker, dealer, analyst, or adviser. We hold no investment licenses and may not sell, offer to sell or offer to buy any security. Our publications are not a recommendation to buy or sell a security.

Section 17(b) of the 1933 Securities and Exchange Act requires publishers who distribute information about publicly traded securities for compensation, to disclose who paid them, the amount, and the type of payment. In order to be in full compliance with the Securities Act of 1933, Section 17(b), we are disclosing that SMMG is compensated $5,000 per month by Plandai Biotechnology for content development. Neither SMMG nor anyone associated with it owns shares in PLPL.

For more information: http://www.stockmarketmediagroup.com.

Go here to see the original:
Plandai Biotechnology Sets Aggressive Agenda for 2017 - Yahoo Finance

Top 5 Vendors in the Biotechnology Reagents Market From 2017 to 2021: Technavio – Yahoo Finance

LONDON--(BUSINESS WIRE)--

Technavio has announced the top five leading vendors in their recent global biotechnology reagents market report. This research report also lists four other prominent vendors that are expected to impact the market during the forecast period.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170425006359/en/

The global biotechnology market is a continuously growing market and has witnessed a speedy growth in past few years. The increase in bio-related technologies, research labs, and centers and commercial requests are the main reasons behind the growth of the global biotechnology reagents market. Increasing investment in R&D of biotechnology, from private and government sector, is the key driver for the growth of the global biotechnology reagents market.

Competitive vendor landscape

According to the report, the global biotechnology reagents market consists of a sizeable number of key global players, along with regional and local players. These players have a vast geographical presence with huge production facilities located, globally. There are a considerable number of small regional vendors with significant shares in the market

The major players compete depending on the innovations, price, and quality of the product. Some players can capture the market due to lower costs compared to their competitors. Also, few suppliers financial, technological, and other resources are better as compared with their competitors who can adapt to the changes in the market demand, says Ajay Adhikari, a lead bio-chemicals and bio-materials research analyst from Technavio.

Looking for more information on this market? Request a free sample report

Technavios sample reports are free of charge and contain multiple sections of the report including the market size and forecast, drivers, challenges, trends, and more.

Top five biotechnology reagents market vendors

Agilent Technologies

Agilent Technologies is one of the leading companies in the biotechnology reagents market. The company produces control reagents, blocking reagents, buffers, diluents, and lysing, fixation, and permeabilization reagents.

BD

BD is one of the major biotechnology reagents producing companies. The company offers reagents for research, clinical, and custom services. It provides reagents for various applications such as immunoassays, cell-based assays, and clinical research.

Merck

Merck is one of the largest biotechnological reagents manufacturing companies. The company provides a wide range of reagents and solvents for different functions such as DNA and RNA synthesis, in vitro diagnostics, and instrumental inorganic analysis.

Bio-Rad Laboratories

Bio-Rad is one of the key vendors for the biotechnology reagents market. The company provides biotechnology reagents for clinical diagnostics, PCR technology, protein assay, and immunodetection reagents.

Thermo Fisher Scientific

Thermo Fisher Scientific is one of the key vendors in the biotechnology reagents market. The company offer reagents for various applications such as an immunogenic adjuvant, protein gel buffers, nucleic acid gel buffers, flow cytometer buffers and reagents, immunoassay buffers and reagents, protein purification buffers, and diagnostic testing.

Browse Related Reports:

Become a Technavio Insights member and access all three of these reports for a fraction of their original cost. As a Technavio Insights member, you will have immediate access to new reports as theyre published in addition to all 6,000+ existing reports covering segments like industrial gases, olefins, and metals and minerals. This subscription nets you thousands in savings, while staying connected to Technavios constant transforming research library, helping you make informed business decisions more efficiently.

About Technavio

Technavio is a leading global technology research and advisory company. The company develops over 2000 pieces of research every year, covering more than 500 technologies across 80 countries. Technavio has about 300 analysts globally who specialize in customized consulting and business research assignments across the latest leading edge technologies.

Technavio analysts employ primary as well as secondary research techniques to ascertain the size and vendor landscape in a range of markets. Analysts obtain information using a combination of bottom-up and top-down approaches, besides using in-house market modeling tools and proprietary databases. They corroborate this data with the data obtained from various market participants and stakeholders across the value chain, including vendors, service providers, distributors, re-sellers, and end-users.

If you are interested in more information, please contact our media team at media@technavio.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170425006359/en/

MULTIMEDIA AVAILABLE:http://www.businesswire.com/news/home/20170425006359/en/

Go here to see the original:
Top 5 Vendors in the Biotechnology Reagents Market From 2017 to 2021: Technavio - Yahoo Finance

Why Investors remained confident on L Brands, Inc. (LB), Puma Biotechnology, Inc. (PBYI)? – StockNewsJournal


StockNewsJournal
Why Investors remained confident on L Brands, Inc. (LB), Puma Biotechnology, Inc. (PBYI)?
StockNewsJournal
Puma Biotechnology, Inc. (NASDAQ:PBYI), at its latest closing price of $36.85, it has a price-to-book ratio of 6.95, compared to an industry average at 11.13. A lower P/B ratio could mean that the stock is undervalued. This ratio also gives some idea ...
Puma Biotechnology Inc (PBYI) Plunges 6.94% on April 18Equities.com
Here's Why Puma Biotechnology Inc (NASDAQ:PBYI) Is Running Up ...Market Exclusive
Orbis Allan Gray Ltd Has $1335000 Stake in Puma Biotechnology Inc (PBYI)The Cerbat Gem
TopChronicle -WsNews 4investors -Markets Daily
all 36 news articles »

See the original post here:
Why Investors remained confident on L Brands, Inc. (LB), Puma Biotechnology, Inc. (PBYI)? - StockNewsJournal

iShares NASDAQ Biotechnology Index (IBB) Receives Consensus Rating of "" from Analysts – The Cerbat Gem


BBNS
iShares NASDAQ Biotechnology Index (IBB) Receives Consensus Rating of "" from Analysts
The Cerbat Gem
iShares NASDAQ Biotechnology Index logo Shares of iShares NASDAQ Biotechnology Index (NASDAQ:IBB) have been given an average broker rating score of 0.00 () from the zero analysts that provide coverage for the company, Zacks Investment Research ...
Courier Capital LLC Continues to Hold Stake in iShares NASDAQ Biotechnology Index (IBB)BBNS
iShares NASDAQ Biotechnology Index (IBB) Upgraded by Vetr Inc. to BuyTranscript Daily
Vetr Inc. Upgrades iShares NASDAQ Biotechnology Index (IBB) to "Buy"Sports Perspectives
Breaking Finance News
all 9 news articles »

See the original post here:
iShares NASDAQ Biotechnology Index (IBB) Receives Consensus Rating of "" from Analysts - The Cerbat Gem

Investors Endure Wild Ride in This Biotech Taking on COVID-19 – Motley Fool

Vir Biotechnology (NASDAQ:VIR) may not be a familiar name to many investors. This relatively young biotech went public last October. Backed by infamous investor SoftBank (of WeWork fame) among others, investors in Vir find themselves in a situation where they truly are betting on the jockey. The seasoned biotech veteran George Scangos helms the company following his prior leadership at Biogenand Exelixis. An experienced team surrounds him, supported by a board of directors filled with seasoned executives.

Vir's mission to eradicate the world of infectious diseases makes it a natural candidate to enter the fray pursuing COVID-19 interventions. Companies are racing to be the first to develop a vaccine and a treatment to stymie the spread of the coronavirus, so investors should familiarize themselves with Vir.

Image Source: Getty Images.

Following an IPO priced at $20 per share, Vir's stock stumbled and spent most of the fall in the $12 and $13 range.The stock took on a new life doubling in price in the second half of January. The stock retreated from this short-lived run above $26 back down to the high teens in the middle of February.

In the last week, the stock has gone parabolic. It closed above $60 per share this week and even broke $70 in pre-market trading on Friday. That's a more than four-fold increase from the start of the year and five times what it traded for most of last year.

Then, boom. Friday morning stock precipitously fell below $40 per share immediately after the market opened. Roughly $2 billion in valuation wiped out in minutes. Within hours, the stock gained back $1 billion in value only to lose it again. This tremendous volatility makes for a trader's playground but can wrack the nerves of fundamental investors.

Image Source: Getty Images.

My issue has less to do with the research and development per se and more with the valuation. Vir's market cap swelled to more than $6 billion at its peak. Personally, I felt its prior valuation in the $1 billion to $2 billion range was pricey for a company with two early-stage clinical candidates. However, the giant leap in valuation does not appear to be based on new data emerging from Vir's R&D efforts. It stems from an announcement on Feb. 25 that Vir teamed up with WuXi Biologics to develop antibodies to treat the spreading COVID-19 (the coronavirus 2019).

It seems like every few hours, news breaks of more confirmed coronavirusinfections in new locales. The pandemonium continues to swell causing a backlash through the economy and eviscerating stock markets. I commend Vir and WuXi, one of the leading Chinese biotech companies, for allocating resources to tackle this growing challenge. The key will be whether the two drug developers can advance a meaningful therapy and do so in a fairly rapid timeframe.

The company maintains a certain degree of implied credibility because Vir is backed by marquee investors, including the Gates Foundation, it's led by seasoned drug developers, and it boasted a $1 billion-plus market cap prior to the COVID-19 news. It seems reasonable to believe that the company's platform technology can deliver COVID-19-specific antibodies for testing. The timing along with safety and potency remain big question marks for now.

I highlight the credibility factor because some small and micro-cap biotechs are jumping on the COVID-19 bandwagon. Some of these smaller entities are well-intentioned while other unscrupulous groups will never undertake meaningful R&D efforts. This latter cohort aims to piggyback on the momentum of the situation. If the stocks spike, these companies usually raise capital to continue operations. The SEC issued a warning to investors to beware of coronavirus scams. The SEC even halted trading in one such penny stock last week.

I don't believe Vir falls into that category. I think the company will undertake a genuine effort and has lined up a reputable partner. However, in the absence of data, predicting if any product will emerge come from the R&D efforts remains challenging. Further, guessing the value of a COVID-19 treatment is difficult. Is it worth $1 billion in market cap, half of that, or multiples more? Nobody really knows. It will depend on how widespread the outbreak is at the time of commercialization, which countries are most in need, and what price the drug will ultimately command.

Biotech investing is not for the faint of heart. The volatility in Vir's stock and high valuation make me cautious. Additionally, Vir faces competition such asGilead Sciences (NASDAQ:GILD), which kicked off two phase 3 clinical trials this week for its promising drug aimed at COVID-19. For now, I will watch Vir from the sidelines and wish the team well on developing a successful treatment.

Originally posted here:
Investors Endure Wild Ride in This Biotech Taking on COVID-19 - Motley Fool

Vir Biotechnology and WuXi Biologics Announce Collaboration for Global Development of Antibodies to Treat COVID-19 – Yahoo Finance

SAN FRANCISCO and SHANGHAI, China, Feb. 25, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc.(VIR) and WuXi Biologics (stock code: 2269.HK) today announced a development and manufacturing collaboration to advance and produce human monoclonal antibodies for the potential treatment of COVID-19 (Coronavirus Disease 2019), a disease caused by SARS-CoV-2.

Under the terms of the agreement, the companies will work together on the clinical development, manufacturing, and commercialization of Virs proprietary antibodies. WuXi Biologics will conduct cell-line development, process and formulation development, and initial manufacturing for clinical development. If the antibodies receive regulatory approvals, WuXi Biologics has the rights to commercialize therapies in Greater China, and Vir has the rights to commercialize therapies in all other markets worldwide.

Vir has identified a number of monoclonal antibodies that bind to SARS-CoV-2. These antibodies were isolated from individuals who had survived a SARS (Severe Acute Respiratory Syndrome) infection. The company is conducting research to determine if its antibodies, or additional antibodies that it may be able to identify, can be effective as treatment and/or prophylaxis against SARS-CoV-2.

We are acutely aware of the importance of moving rapidly in response to COVID-19, said George A. Scangos, Ph.D., CEO of Vir Biotechnology. In the event that we are in a position to develop an antibody therapy, our agreement with WuXi Biologics enables us to accelerate advancement against this global threat.

Both WuXi Biologics and Vir felt the great urgency to develop antibodies to treat global patients provided they work in the clinic. Our state-of-the-art technology platform and robust global-quality supply network make us uniquely qualified in expediting the development and manufacturing of these potential treatments," commented Chris Chen, Ph.D., CEO of WuXi Biologics. "Once again WuXi Biologics is collaborating with global biotech companies such as Vir to expedite biologics development to benefit patients worldwide."

About Virs Antibody Platform

Vir has a robust method for capitalizing on unusually successful immune responses naturally occurring in people who are protected from, or have recovered from, infectious diseases. The platform is used to identify rare antibodies from survivors that have the potential to treat and prevent rapidly evolving and/or previously untreatable pathogens via direct pathogen neutralization and immune system stimulation. Vir engineers the fully human antibodies that it discovers to enhance their therapeutic potential. This platform has been used to identify and develop antibodies for pathogens including Ebola (mAb114, currently in use in theDemocratic Republic of Congo), hepatitis B virus, influenza A, malaria, and others.

AboutVir Biotechnology

Vir Biotechnologyis a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of five product candidates targeting hepatitis B virus, influenza A, human immunodeficiency virus and tuberculosis. For more information, please visit http://www.vir.bio.

About WuXi Biologics

WuXi Biologics (stock code: 2269.HK), a Hong Kong-listed company, is a leading global open-access biologics technology platform offering end-to-end solutions to empower organizations to discover, develop and manufacture biologics from concept to commercial manufacturing. Our company history and achievements demonstrate our commitment to providing a truly ONE-stop service offering and strong value proposition to our global clients. As of June 30, 2019, there were a total of 224 integrated projects, including 106 projects in pre-clinical development stage, 102 projects in early-phase (phase I and II) clinical development, 15 projects in late-phase (phase III) development and one project in commercial manufacturing. With total estimated capacity for biopharmaceutical production planned in China, Ireland, Singapore and the U.S. exceeding 280,000 liters by 2022, we will provide our biomanufacturing partners with a robust and premier-quality global supply chain network. For more information on WuXi Biologics, please visit http://www.wuxibiologics.com.

Story continues

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as may, will, expect, plan, anticipate, estimate, intend, potential and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Virs expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this press release include statements regarding the companys efforts to neutralize the SARS-CoV-2 virus and identify additional potential therapies for SARS-CoV-2, and its ability to address the emerging public health epidemic. Many factors may cause differences between current expectations and actual results including unexpected safety or efficacy data observed during preclinical or clinical studies, challenges in neutralizing SARS-CoV-2, difficulty in collaborating with other companies or government agencies, and challenges in accessing manufacturing capacity withinChina. Other factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Virs filings with theU.S. Securities and Exchange Commission, including the section titled Risk Factors contained therein. Except as required by law, Vir assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

Contact:

Vir Biotechnology, Inc.

InvestorsNeera Ravindran, MDHead of Investor Relations & Strategic Communicationsnravindran@vir.bio+1-415-506-5256

MediaLindy DevereuxScient PRlindy@scientpr.com+1-646-515-5730

WuXi Biologics

MediaKevin Huang PhDkevin_huang@wuxiapptec.com

The rest is here:
Vir Biotechnology and WuXi Biologics Announce Collaboration for Global Development of Antibodies to Treat COVID-19 - Yahoo Finance

Researchers identify roots of childhood asthma – European Biotechnology

Infants who show defective immune responses to microbial components are more likely to acquire asthma later in childhood, according to a study of 541 children.

The discovery of a team headed by Hans Bisgaard at Gentofte Hospital in Gentofte, Denmark, reveals that childhood asthma is closely intertwined with the behaviour of the immune system early in life a finding that could open the door to new diagnostics and preventative strategies.

The immune system develops as immune cells begin to respond to different types of microbes from the environment. This early stage of development is critical: any persistent abnormalities can trigger chronic inflammation and may raise the risk of asthma and other allergic diseases.

To flesh out the connection between early-life immunity and asthma, first author Anna Thysen et al. studied a longitudinal cohort of 541 children, by analysing blood samples collected at 18 months and comparing these immune profiles to clinical outcomes at six years of age. The scientists exposed blood cells gathered from the 18 month olds to different molecules from viruses, bacteria and fungi. They observed that neutrophils of the innate immune system from some infants responded too strongly to certain viruses, and these same infants were more susceptible to transient asthma as they approached the age of six. Furthermore, some infants harboured T cells that produced excessive amounts of IL-5 and IL-13 two pro-inflammatory cytokines associated with asthma and were more likely to have developed persistent asthma at six years of age.

Thysenet al.speculate that future blood tests to detect abnormal immune signatures in infants might allow for earlier prevention or treatment of childhood asthma.

See the original post:
Researchers identify roots of childhood asthma - European Biotechnology

Generex Biotechnology Announces Interview with Richard Purcell, Executive Vice President of R&D – Yahoo Finance

Interview available online on CEO Roadshow

MIRAMAR, Fla., Jan. 24, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (GNBT) today announced that Richard Purcell, the companys Executive Vice President of Research & Development conducted an interview with Mike Elliott of CEO Roadshow, which is available at:

or

During the interview, Mr. Purcell spoke about rebuilding Generex in 2019 and transforming the company through acquisitions and restructuring to create a new vision for delivering care for patients with chronic and complex health needs. Mr. Purcell stated, We are partnering with large primary care and specialty physician practices through patient-focused MSOs that are designed to deliver integrated and collaborative care. In the coming era of outcomes-driven medicine, NuGenerex Health is building end-to-end solutions that improve patient outcomes and enhance practice profitability. We are dedicated to strengthening the doctor/patient relationship by providing cutting edge drugs, medical devices, therapies, and services from the NuGenerex family of subsidiary companies. In 2020, we are poised for growth. We plan to restart our orthopedic/podiatric MSO with new product lines from our subsidiaries Olaregen, Pantheon and MediSource, and the introduction of our software and service offering, DME-IQ. In addition, we plan to launch our integrated care model for diabetes with our physician partners in Arizona. And perhaps most exciting, the ALTuCELL acquisition is expected to close in the near future, and we plan to initiate a clinical development program to treat and potentially cure diabetes with cellular therapy.

About Generex Biotechnology Corp. Generex Biotechnology is an integrated healthcare holding company with end-to-end solutions for patient centric care from rapid diagnosis through delivery of personalized therapies. Generex is building a new kind of healthcare company that extends beyond traditional models providing support to physicians in an MSO network, and ongoing relationships with patients to improve the patient experience and access to optimal care.

Cautionary Note Regarding Forward-Looking Statements

This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plan," "believes," "will," "achieve," "anticipate," "would," "should," "subject to" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

Generex Contact:

Generex Biotechnology Corporation

Joseph Moscato 646-599-6222

Todd Falls 1-800-391-6755 Extension 222 investor@generex.com

Read the original here:
Generex Biotechnology Announces Interview with Richard Purcell, Executive Vice President of R&D - Yahoo Finance

Cyclica and AUM Biosciences to Partner on Developing Novel Cancer Therapies with Greater Precision and Speed, under Project Nexus – BioSpace

Jan. 15, 2020 14:00 UTC

TORONTO & SINGAPORE--(BUSINESS WIRE)-- AUM Biosciences (AUM), a Singapore-headquartered clinical-stage biotechnology company committed to speedily developing affordable cancer therapies, and Cyclica, a Toronto-based biotechnology company leveraging AI and computational biophysics to decentralize drug discovery, today announced a partnership under Project Nexus to apply Cyclicas proprietary drug discovery platform in AUMs diverse R&D programs for the early-stage discovery of novel cancer therapies.

While there has been remarkable progress over the past few decades, cancer remains a major concern, with one in every six deaths being related to cancer. With the complex nature of cancer, researchers are faced with challenges in developing effective and affordable cancer treatments using classical drug discovery approaches, which ultimately results in barriers to affordability and availability of life-saving medicines for patients in need.

In this strategic partnership, AUM will deploy its drug development expertise, including a biomarker-driven approach, and utilize Cyclicas integrated AI-augmented and structure-based platform, Ligand Design and Ligand Express, which together will design advanced lead-like molecules that minimize unwanted off-target effects while providing a holistic understanding of a molecule's activity through integrated systems biology and structural pharmacogenomics.

The ability to delve deeper into complex medical outcomes enhances the potential for discovery and assessment of novel molecules while in the development stage, which reduces the risk of failure and expedites the process, said Vishal Doshi, CEO of AUM Biosciences. We are excited about this partnership with Cyclica, which will help us discover the undiscovered to address the needs of patients in Asia.

Cyclicas goal is to decentralize the discovery of medicines by partnering with hyper innovative biotechs globally. We are impressed with AUMs expertise in drug development and our shared passion for tackling disease areas that are among the most intricate and impactful, says Cyclicas President & CEO, Naheed Kurji.

Cyclica will receive an upfront payment as well as milestone payments upon the completion of specific stages for Project Nexus. AUM will maintain rights for future development and commercialization of drug assets resulting from Project Nexus.

About AUM Biosciences

AUM Biosciences (AUM) is an oncology-focused Asian biotechnology company committed to developing affordable cancer therapies. AUM is dedicated to revolutionize the existing inefficient drug development paradigm by harnessing the power of precision medicine and digitization. AUM focuses on early stage development of innovative treatment of cancers prevalent in Asia with the potential to address global markets. Led by a highly-experienced management team with over 100 years of oncology drug development experience combined, AUM is disrupting the drug development paradigm by implementing a holistic approach to developing drugs. Headquartered in Singapore, AUM is strategically positioned to work, partner and collaborate with leading research institutes, clinicians and pharmaceutical companies globally. AUM is the recipient of Frost & Sullivans 2019 Asia-Pacific Biotech Entrepreneurial Company of the Year. AUM current pipeline includes global rights for 2 first-in-class drugs, Mnk Inhibitor (AUM001), and Pan PIM/PI3K/mTOR Inhibitor (AUM302). AUM001 is currently undergoing Phase I and expected to be Phase II ready by mid 2020. For more information, please visit http://www.aumbiosciences.com

About Cyclica, Inc

Cyclica is a Toronto, Canada based biotechnology company that is decentralizing the discovery of new medicines with its integrated structure-based and AI-augmented drug discovery platform, Ligand Design and Ligand Express. Taken together Ligand Design and Ligand Express design advanced lead-like molecules that minimize unwanted off-target effects, while providing a holistic understanding of a molecule's activity through integrated systems biology and structural pharmacogenomics. Cyclicas differentiated platform opens new opportunities for drug discovery, including multi-targeted and multi-objective drug design, lead optimization, ADMET-property prediction, target deconvolution, and drug repurposing for a wide range of indications. With a world--class team with deep roots in industry and a first-in-class integrated drug discovery platform, Cyclica will spark a surge of innovation through a combination of venture creation and partnerships with early-stage and emerging biotech companies. By doing more with AI, Cyclica will revolutionize a system troubled with attrition and costly failures, accelerate the drug discovery process, and develop medicines with greater precision.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200115005475/en/

See more here:
Cyclica and AUM Biosciences to Partner on Developing Novel Cancer Therapies with Greater Precision and Speed, under Project Nexus - BioSpace

Unity Biotechnology (NASDAQ:UBX) Stock Rating Reaffirmed by Cantor Fitzgerald – Riverton Roll

Cantor Fitzgerald reissued their overweight rating on shares of Unity Biotechnology (NASDAQ:UBX) in a report released on Thursday, December 12th, BenzingaRatingsTable reports. The brokerage currently has a $20.00 price target on the stock.

A number of other equities research analysts have also recently weighed in on UBX. Zacks Investment Research upgraded Unity Biotechnology from a sell rating to a buy rating and set a $8.25 price target on the stock in a research note on Wednesday, December 11th. Mizuho restated a buy rating and issued a $33.00 price target on shares of Unity Biotechnology in a research note on Monday, November 18th. One investment analyst has rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of Buy and a consensus price target of $18.81.

NASDAQ UBX opened at $7.10 on Thursday. The company has a market cap of $327.11 million, a PE ratio of -2.80 and a beta of 0.01. Unity Biotechnology has a 12 month low of $5.61 and a 12 month high of $16.87. The stock has a 50 day moving average of $7.38 and a 200-day moving average of $7.21.

Unity Biotechnology (NASDAQ:UBX) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.54) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.05). As a group, equities analysts predict that Unity Biotechnology will post -1.99 EPS for the current fiscal year.

Several hedge funds and other institutional investors have recently modified their holdings of UBX. Tower Research Capital LLC TRC bought a new position in shares of Unity Biotechnology in the third quarter worth $45,000. Bank of Montreal Can boosted its stake in Unity Biotechnology by 164,400.0% in the second quarter. Bank of Montreal Can now owns 4,935 shares of the companys stock valued at $47,000 after buying an additional 4,932 shares in the last quarter. Aperio Group LLC acquired a new stake in Unity Biotechnology in the second quarter valued at about $50,000. Squarepoint Ops LLC acquired a new stake in Unity Biotechnology in the third quarter valued at about $82,000. Finally, Ellington Management Group LLC acquired a new stake in Unity Biotechnology in the second quarter valued at about $103,000. Institutional investors own 35.56% of the companys stock.

Unity Biotechnology Company Profile

Unity Biotechnology, Inc, a biotechnology company, engages in the research and development of therapeutics to extend human health span. The company's lead drug candidates include UBX0101 that is in Phase 1 clinical study for musculoskeletal disease; and UBX1967 for ophthalmologic diseases. It is also developing programs in pulmonary disorders.

Recommended Story: What are the benefits of a balanced fund?

Receive News & Ratings for Unity Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unity Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.

View original post here:
Unity Biotechnology (NASDAQ:UBX) Stock Rating Reaffirmed by Cantor Fitzgerald - Riverton Roll

Biotechnology – PRIDCO

Puerto Rico. The Bio Island.

Puerto Rico enjoys a long legacy in pharmaceutical and medical device manufacturing. Biologics are also a growing segment of the island's life sciences sector. Amgen, Eli Lilly, Abbott and Becton Dickinson Bioscience alone have invested more than $65.9 million in four plants since 2005. Puerto Rico also boasts the world's largest modular biotechnology plant for producing recombinant human insulin.

Growing Agricultural Biotechnology Sector

Puerto Rico has also emerged as an important center for agricultural biotechnology. Pioneer Hi-Bred, BASF Agrochemical, Bayer-Cropscience, Syngenta Seeds and Rice Tec are among many seed companies that have found the island to be fertile ground for R&D with our tropical weather, consistent water supply, ease of commerce with the U.S., attractive incentives and top-quality agricultural science talent.

A Highly Educated Workforce

Puerto Rico's workforce has vast knowledge in GMP, FDA and other global regulations, while the island's university system turns out a steady stream of new talent:

Helpful Links:

Visit link:
Biotechnology - PRIDCO